Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.
- Authors
- Ashenhurst, James R; Bujarski, Spencer; Ray, Lara A
- Year
- 2012
- Journal
- Pharmacology, biochemistry, and behavior
- PMID
- 22954510
- DOI
- 10.1016/j.pbb.2012.08.019
- PMCID
- PMC3683577
Naltrexone, one of four FDA-approved pharmacotherapies for alcohol dependence, has shown moderate efficacy in clinical trials. Pharmacogenetic effects have been reported such that allelic variation at the gene encoding the mu-opioid receptor (OPRM1, rs1799971) predicts naltrexone-induced blunting of the positively reinforcing effects of alcohol. However, naltrexone also binds, albeit to a lesser degree, to kappa and delta opioid receptors in the brain. This alternate binding presents the possibility that single nucleotide polymorphisms (SNPs) in the kappa and delta opioid receptor (OPRK1 and OPRD1) genes may contribute to naltrexone pharmacogenetics. Therefore, the goal of this exploratory study was to re-examine data from a double-blind placebo controlled laboratory trial of naltrexone for pharmacogenetic effects at kappa and delta opioid receptor tag SNPs. Participants were 40 heavy drinkers (12 female) who underwent an intravenous alcohol challenge paradigm after receiving naltrexone (50mg) or placebo in randomized and crossover fashion. Dependent variables were self-reported alcohol-induced stimulation, sedation, and craving. Multilevel models revealed a significant Naltrexone×OPRK1 Genotype (rs997917) interaction predicting alcohol-induced sedation, such that TT homozygotes reported lower naltrexone-induced alcohol sedation as compared to carriers of the C allele. Moreover, there was a significant Naltrexone×OPRD1 Genotype (rs4654327) interaction predicting alcohol-induced stimulation and craving, such that carriers of the A allele at this locus reported greater naltrexone-induced blunting of alcohol stimulation and alcohol craving compared to GG homozygotes. These findings suggest that additional pharmacogenetic effects in the opioid receptor system may account for individual differences in response to naltrexone in the human laboratory.
LD plot from Haploview 4.1 for EA subjects based on HapMap (phase II) data for individuals of European Ancestry for the (A) OPRD1 and (B) OPRK1 tSNPs examined in this study. Pair-wise SNP |D′| values (×100) of linkage are shown along with 2 haplotype blocks identified using the four-gamete rule. Darkened blocks indicate SNP pairs without evidence of extensive recombination (i.e., 4-gamete rule for haplotype block characterization with at least one 2-SNP haplotype having a frequency < 0.02).
Effect of OPRK1^2 genotype on sedation while on naltrexone versus placebo. Data presented are predicted values based on betas from mixed-model regression analyses. TT homozygotes showed reduced sedation while on naltrexone.
Effect of OPRD10^4 genotype on alcohol-induced stimulation while on naltrexone versus placebo. Data presented are predicted values based on betas from mixed-model regression analyses. A-allele carriers showed naltrexone-induced blunting of alcohol stimulation. An asterisk (** p < 0.01) indicates a significant effect of medication within a genotype group across the infusion session
Effect of OPRD1^4 genotype on alcohol craving while on naltrexone versus placebo. Data presented are predicted values based on betas from mixed-model regression analyses. A-allele carriers showed naltrexone-induced attenuation of alcohol craving. An asterisk (* p < 0.05) indicates a significant effect of medication within a genotype group across the infusion session.
| Name | Type |
|---|---|
| A118G SNP | variant |
| A allele | cohort |
| African American | cohort |
| alcohol | phenotype |
| alcohol abuse | phenotype |
| alcohol dependence | phenotype |
| Alcohol dependent human subjects local | cohort |
| Alcohol high local | phenotype |
| alcohol-induced sedation local | phenotype |
| Alcohol-induced sedation local | phenotype |
| alcoholism | phenotype |
| alcohol sensitivity | phenotype |
| alcohol stimulation | phenotype |
| Alcohol urge questionnaire | phenotype |
| Alcohol Use Disorder | phenotype |
| Alcohol Use Disorders Identification Test (AUDIT) local | phenotype |
| Asian | cohort |
| AUDIT | phenotype |
| Biphasic Alcohol Effects Scale | phenotype |
| Boulder, Colorado community participants local | cohort |
| BrAC | phenotype |
| breath alcohol concentration (BrAC) local | phenotype |
| Chinese | cohort |
| clinical study of naltrexone local | cohort |
| Combine Study | cohort |
| confusion | phenotype |
| craving | phenotype |
| craving effects local | phenotype |
| CTOP local | drug |
| DAMGO | drug |
| delta opioid agonist local | drug |
| delta opioid receptor | drug |
| dopamine | drug |
| DRD2 | gene |
| drinking | phenotype |
| Drinks per drinking episode local | phenotype |
| Endogenous opioid local | drug |
| ethanol consumption | phenotype |
| ethanol preference | phenotype |
| European ancestry | cohort |
| fatigue | phenotype |
| G allele | variant |
| GCRC local | cohort |
| genomic DNA | drug |
| HapMap | cohort |
| hazardous drinking | phenotype |
| heavy drinking | phenotype |
| Hispanic | phenotype |
| kappa agonist local | drug |
| kappa opioid receptor | drug |
| Liking local | phenotype |
| medication | drug |
| mice | cohort |
| midbrain | anatomy |
| morphine | drug |
| mu opioid receptor | drug |
| naloxone | drug |
| naltrexone | drug |
| Naltrexone clinical trials local | cohort |
| Naltrindole local | drug |
| nucleus accumbens | anatomy |
| opioid receptor SNPs local | variant |
| Oprd1 | cohort |
| OPRD1^1 local | variant |
| OPRD1^2 local | variant |
| OPRD1^3 local | variant |
| OPRD1^5 local | variant |
| OPRD1 G allele local | variant |
| OPRK local | gene |
| OPRK1 | cohort |
| OPRK1^1 local | variant |
| OPRK1 C allele local | variant |
| OPRK1 SNP local | variant |
| OPRK^2 local | variant |
| OPRM1 | cohort |
| OPRM1 A118G | cohort |
| OPRM1 A118G SNP local | variant |
| participants | cohort |
| pharmacogenetic response local | phenotype |
| placebo-controlled laboratory study of naltrexone local | cohort |
| rats | cohort |
| Reinforcing effects local | phenotype |
| relapse | phenotype |
| relapse rates | phenotype |
| riboflavin local | drug |
| rs2236856 local | variant |
| rs4654327 | variant |
| rs499062 local | variant |
| rs508448 local | variant |
| rs529520 local | variant |
| rs581111 local | variant |
| rs678849 local | variant |
| rs6985606 | variant |
| rs760588 local | variant |
| rs963549 local | variant |
| rs997917 | variant |
| saline | drug |
| sedative effects | phenotype |
| sedatives | drug |
| sex | phenotype |
| stimulant effects | drug |
| stimulation | phenotype |
| study completers | cohort |
| study medication | drug |
| subjective intoxication | phenotype |
| time to relapse | phenotype |
| urine | drug |
| ventral pallidum | anatomy |
| ventral tegmental area | anatomy |
| Voluntary drinking local | phenotype |
| White | phenotype |
| whites | cohort |
| β-endorphin | drug |
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers. | Farahbakhsh ZZ et al. | — | 2026 | → |
| Introduction: Approved treatments for alcohol use disorder by regulatory agencies. | Camarini R et al. | — | 2024 | → |
| Association of <i>OPRK1</i> rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes. | Özkan-Kotiloğlu S et al. | — | 2023 | → |
| Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms. | Özkan-Kotiloğlu S et al. | — | 2023 | → |
| Alcohol Use Disorder: Neurobiology and Therapeutics. | Yang W et al. | — | 2022 | → |
| KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway. | Estave PM et al. | — | 2022 | → |
| Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates. | Terasaki D et al. | — | 2022 | → |
| Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. | Lashgari NA et al. | — | 2021 | → |
| Developmental Considerations for the Use of Naltrexone in Children and Adolescents. | Stancil SL et al. | — | 2021 | → |
| Haplotype-based association study of Opioid Receptor Kappa-type 1 (OPRK1) gene polymorphisms with nicotine dependence among male smokers. | Albonaim A et al. | — | 2021 | → |
| Overview of Genetic Analysis of Human Opioid Receptors. | Spampinato SM | — | 2021 | → |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | — | 2020 | → |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | — | 2020 | → |
| Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. | Roche DJO et al. | — | 2019 | → |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | — | 2019 | → |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | — | 2019 | → |
| The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. | de Laat B et al. | — | 2019 | → |
| A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. | Schuckit MA | — | 2018 | → |
| Delta Opioid Pharmacology in Relation to Alcohol Behaviors. | Alongkronrusmee D et al. | — | 2018 | → |
| Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population. | Albonaim A et al. | — | 2017 | → |
| Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol. | Anderson RI et al. | — | 2017 | → |
| Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development. | Courtney KE et al. | — | 2016 | → |
| From genetic studies to precision medicine in alcohol dependence. | Sun Y et al. | — | 2016 | → |
| Nociceptin/orphanin FQ receptor gene variation is associated with smoking status in Japanese. | Kasai S et al. | — | 2016 | → |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | — | 2016 | → |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | — | 2016 | → |
| Clinically relevant genetic biomarkers from the brain in alcoholism with representation on high resolution chromosome ideograms. | Manzardo AM et al. | — | 2015 | → |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | — | 2015 | → |
| The pharmacogenetics of alcohol use disorder. | Jones JD et al. | — | 2015 | → |
| Alcohol-medical drug interactions. | Johnson BA et al. | — | 2014 | → |
| Challenges in paediatric procedural sedation: political, economic, and clinical aspects. | Mason KP | — | 2014 | → |
| Genetics and genomics of alcohol sensitivity. | Morozova TV et al. | — | 2014 | → |
| Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. | Courtney KE et al. | — | 2014 | → |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | — | 2014 | → |
| Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. | Sobczak M et al. | — | 2014 | → |
| An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. | Crist RC et al. | — | 2013 | → |
| A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. | Xu K et al. | — | 2013 | → |
| Endogenous opiates and behavior: 2012. | Bodnar RJ | — | 2013 | → |
| Opioid system genes in alcoholism: a case-control study in Croatian population. | Cupic B et al. | — | 2013 | → |